Sarah trained as a doctor in London before undertaking her Medical Oncology specialist training in Cambridge and the Royal Marsden Hospital. In 2003 she completed a PhD at Cambridge University in fruit fly genetics followed by a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.
From 2006-2015, Sarah was a Senior Lecturer at Imperial College London and led their Early Cancer Trials Unit. In 2015 she moved to the University of Oxford where she is now Professor of Medical Oncology, Director of Oncology Clinical Trials Office (OCTO), lead for Oxford Early Cancer Medicine Centre (ECMC) and runs a molecular biology laboratory exploring protein synthesis in cancer.
Sarah has been chief or principal investigator for a number of national and international cancer studies. She has worked with the MHRA/NICE to develop guidance for their new pathways to approval and advises biotechnology and pharmaceutical companies on cancer drug development.
